Latest available resultsQuarter ended June 30, 202610-Q · July 30, 2026
Filed with the SECBRISTOL MYERS SQUIBB CO
BMYPharma & biotech
Next reportOctober 29, 2026Analyst forecast 1.74 $/share
Revenue
$12.97B
▲ +5.7% vs prior year% YoY
Net income
$3.32B
▲ +153.2% vs prior year% YoY
EPS
1.62$
▲ +153.1% vs prior year% YoY
Net margin
25.6%
▲ +14.9 percentage points vs prior year pp YoY
Revenue▲ +5.7 %
Margins (% of revenue)GrossOperating N/ANet
Net income▲ +153.2 %
EPS▲ +153.1 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $12.97B | |
| Gross profit | $9.25B | 71.3 % |
| Operating income | — | |
| Net income | $3.32B | 25.6 % |
| R&D | $2.96B | 22.8 % |
| EPS (diluted) | 1.62 $ | |
| Balance sheet | ||
| Assets | $87.63B | |
| Liabilities | $65.31B | |
| Equity | $22.32B | |
| Cash | $8.72B | |
| Capital | ||
| Shares outstanding | 2.04B | as of 2026-07-22 |
| Public float | — | |